LL-37
Animal / preclinicalAlso known as: Cathelicidin fragment
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
The body's own front-line antimicrobial peptide, with a large research literature on host defence and wound healing. Its biology is genuinely double-edged (context-dependent pro- and anti-inflammatory roles), and injectable product use runs ahead of the human trial base.
Mechanism
Host-defence peptide with direct antimicrobial activity plus immunomodulatory and wound-healing signalling; effects depend heavily on context and concentration.
Evidence
Rich preclinical literature on host defence and wound repair; supplemental human use hasn't been trialled, and the context-dependent biology matters.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Short.
Storage
Refrigerate solutions.
Commonly reported side effects
- Not well characterised in humans
- Injection-site reactions reported anecdotally
Legal status by region
- USNot FDA-approved for human use.
Legal status changes over time; verify locally before relying on this.